drugset / Trial / NCT04606394

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

NCT04606394

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients

Timeline

Start
2020-12-02
Primary completion
2021-12-15
Completion
2021-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 90 ug Inhaled
Subject Trelegy Ellipta Unknown 25 ug Inhaled
Subject Trelegy Ellipta Unknown 62.5 ug Inhaled
Subject Trelegy Ellipta Unknown 100 ug Inhaled